RTs Three Key Takeaways: No Separate Indication Needed: The European Medicines Agency (EMA) has determined that Eli Lillys Mounjaro (tirzepatide), approved for weight management, does not require a separate indication for treating obstructive sleep apnea (OSA) in adults with obesity
Eli Lilly and Company leveraged its dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound) to capture significant market share across diabetes and obesity indications
Conversely, severe constipation unresponsive to increased fluid intake, dietary fibre, and over-the-counter laxatives should also be discussed
Pifithrin- induces necroptosis through oxidative mitochondrial damage but accompanies epithelialmesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis
The advancement of biosimilars and more economical production techniques may alleviate these issues
It can affect clothing size, mobility, sleep apnea symptoms, blood pressure, and how close they get to a personal goal weight
